Despite the significant progress in anticancer drug development over recent years, there is a vital need for newer agents with unique, but still effective, mechanisms of action order to treat disease, particularly highly aggressive and drug-resistant types. Alkylating agents, particular nitrogen-based alkylators, are commonly used hematological solid malignancies; they exert their antineoplasti...